Filing Details

Accession Number:
0000939767-17-000042
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-03-21 19:28:39
Reporting Period:
2017-03-20
Filing Date:
2017-03-21
Accepted Time:
2017-03-21 19:28:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
939767 Exelixis Inc. EXEL Services-Commercial Physical & Biological Research (8731) 043257395
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1202098 Stelios Papadopoulos C/O Exelixis, Inc.
210 E. Grand Ave.
South San Francisco CA 94080
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-03-20 10,000 $10.53 1,238,471 No 4 M Direct
Common Stock Disposition 2017-03-20 10,000 $21.66 1,228,471 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option (right to buy) Disposition 2017-03-20 10,000 $0.00 10,000 $10.53
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2007-05-02 2017-05-01 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 10,000 Indirect By Trust
Footnotes
  1. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.66 to $21.68. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4.
  2. Shares are held by Fondation Sante, of which the Reporting Person is co-trustee.
  3. The option, representing the right to purchase a total of 10,000 shares of Exelixis, Inc. common stock, became fully exercisable on May 2, 2007.